Solange M. Sanches

211 Professor Antonio Prudente Street
Ararai, ES 01509900, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Journal: JCO oncology practice

Published: March 06, 2026

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.

Journal: NPJ breast cancer

Published: February 20, 2026

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Journal: Breast cancer research and treatment

Published: November 22, 2025

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Journal: NPJ breast cancer

Published: November 02, 2025

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.

Journal: Breast cancer research and treatment

Published: August 11, 2025

MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients.

MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients.

Journal: The British journal of radiology

Published: May 09, 2025

MRI Response to Neoadjuvant Chemotherapy and Prognostic Implications in Breast Cancer Patients.

MRI Response to Neoadjuvant Chemotherapy and Prognostic Implications in Breast Cancer Patients.

Journal: The British journal of radiology

Published: May 09, 2025

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Journal: Breast (Edinburgh, Scotland)

Published: May 04, 2025

Diagnostic performance of MRI in predicting pathological response in patients with triple-negative breast carcinomas undergoing neoadjuvant chemotherapy and immunotherapy.

Diagnostic performance of MRI in predicting pathological response in patients with triple-negative breast carcinomas undergoing neoadjuvant chemotherapy and immunotherapy.

Journal: European radiology

Published: April 04, 2025

Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.

Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.

Journal: Cancer medicine

Published: February 09, 2023

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Journal: Therapeutic advances in medical oncology

Published: September 21, 2022

Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer.

Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer.

Journal: Immunology

Published: January 29, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026